Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6844956 | 0.76 | CHRNA7 (0.34) | CHRNA7HTR3AKCNH2EGFRKDR | |
| SCHEMBL12963781 | 0.76 | CHRNA7 (0.32) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL28458977 | 0.70 | — | — | |
| SCHEMBL25219260 | 0.66 | CHRNA7 (0.38) | CHRNA7HTR3AKCNH2EGFRKDR | |
| SCHEMBL24969531 | 0.65 | EGLN1 (0.31) | — | |
| SCHEMBL4047301 | 0.65 | KDR (0.51) | CHRNA7HTR3AKCNH2EGFRKDR | |
| SCHEMBL20263174 | 0.65 | NPC1 (0.36) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL23747116 | 0.65 | CHRNA7 (0.35) | CHRNA7HTR3AKCNH2EGFRKDR | |
| SCHEMBL24393338 | 0.64 | ALDH1A1 (0.33) | EGFRKDR | |
| SCHEMBL23747152 | 0.64 | CHRNA7 (0.41) | CHRNA7HTR3AKCNH2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-112262139-B | Aminopyrrolotriazines as kinase inhibitors | 百时美施贵宝公司 | 2023-07-25 | — | — | CN | disclosed |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-04 | — | — | US | disclosed |
| CN-114591339-B | Toll-like receptor inhibitor and preparation and application thereof | 上海维申医药有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114591339-A | Toll-like receptor inhibitor and preparation and application thereof | 上海维申医药有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-112262139-A | Aminopyrrolotriazines as kinase inhibitors | 百时美施贵宝公司 | 2021-01-22 | — | — | CN | disclosed |
| EP-3743430-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
| WO-2019147782-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019147782-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | WO | disclosed |
| WO-2015128334-A9 | 3H-THIENO[3,4]PYRIMIDIN-4-ONEAND PYRROLOPYRIMID-4-ONE AS GRAM-POSITIVE ANTIBACTERIAL AGENTS | LABORATOIRE BIODIM (FR) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015128334-A1 | 3H-THIENO[3,4]PYRIMIDIN-4-ONEAND PYRROLOPYRIMID-4-ONE AS GRAM-POSITIVE ANTIBACTERIAL AGENTS | LABORATOIRE BIODIM (FR) | 2015-09-03 | — | — | WO | disclosed |
| EP-2913333-A1 | 3H-thieno[3,4]pyrimidin-4-one and pyrrolopyrimidone as gram-positive antibacterial agents | LABORATOIRE BIODIM (FR) | 2015-09-02 | — | — | EP | disclosed |
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | WANG ZHONG (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | WANG ZHONG (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | WANG ZHONG (US) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | CHRNA7 3933/4885HTR3A 3666/4885KCNH2 1935/4885 |
| US-20120077814-A1 | SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES | NEDD8, NAE1, UBA3 | CHRNA7 3914/4885HTR3A 4167/4885KCNH2 4745/4885 |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | RIPK1, RIPK2, RIPK4 | CHRNA7 3933/4885HTR3A 3666/4885KCNH2 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.